Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo
© Michel et al; licensee BioMed Central Ltd. 2009
Received: 29 July 2008
Accepted: 13 January 2009
Published: 13 January 2009
Cells derived from native rodents have limits at distinct steps of HIV replication. Rat primary CD4 T-cells, but not macrophages, display a profound transcriptional deficit that is ameliorated by transient trans-complementation with the human Tat-interacting protein Cyclin T1 (hCycT1).
Here, we generated transgenic rats that selectively express hCycT1 in CD4 T-cells and macrophages. hCycT1 expression in rat T-cells boosted early HIV gene expression to levels approaching those in infected primary human T-cells. hCycT1 expression was necessary, but not sufficient, to enhance HIV transcription in T-cells from individual transgenic animals, indicating that endogenous cellular factors are critical co-regulators of HIV gene expression in rats. T-cells from hCD4/hCCR5/hCycT1-transgenic rats did not support productive infection of prototypic wild-type R5 HIV-1 strains ex vivo, suggesting one or more significant limitation in the late phase of the replication cycle in this primary rodent cell type. Remarkably, we identify a replication-competent HIV-1 GFP reporter strain (R7/3 YU-2 Env) that displays characteristics of a spreading, primarily cell-to-cell-mediated infection in primary T-cells from hCD4/hCCR5-transgenic rats. Moreover, the replication of this recombinant HIV-1 strain was significantly enhanced by hCycT1 transgenesis. The viral determinants of this so far unique replicative ability are currently unknown.
Thus, hCycT1 expression is beneficial to de novo HIV infection in a transgenic rat model, but additional genetic manipulations of the host or virus are required to achieve full permissivity.
In vivo studies on HIV-1 pathogenesis and the testing of antiviral strategies have been hampered by the lack of an immunocompetent small animal that is fully permissive for infection. The host range and cell tropism of HIV-1 is highly restricted: it can only efficiently replicate in primary and immortalized T-cells and macrophages of human origin. Cells from rats and mice do not or only inefficiently support various steps of the HIV-1 replication cycle [1–6]. Molecular characterization of some of these species-specific barriers has revealed the inability of several rodent orthologues of cellular factors, essential for HIV replication in human cells, to support distinct viral functions. The entry of HIV-1 provides a compelling example: the CD4 binding receptor and the chemokine co-receptors CCR5 or CXCR4 from rodents generally cannot support viral entry [1, 7–10]. Expression of the human HIV-1 receptor complex largely overcomes the entry restriction, and this observation has spured efforts to develop transgenic (-tg) mouse and rat models permissive for HIV replication through a block-by-block humanization (for an overview ). This conceptual approach seeks to surmount intrinsic limitations in the HIV-1 replication cycle in small animals by stable introduction of critical human transgenes into the genome of laboratory rodents using transgene or knock-in technology.
Consequently, we generated Sprague-Dawley rats that transgenically express hCD4 and hCCR5 selectively on CD4 T-cells, macrophages, and microglia , the major targets for productive HIV-1 infection in humans. After a systemic challenge with HIV-1YU-2, these double-tg animals harboured significant levels of HIV-1 cDNAs in lymphatic organs [7, 12, 13], up to 106 HIV-1 cDNA copies per 106 splenocytes , demonstrating a robust susceptibility to HIV-1 in vivo. This level of susceptibility was several orders of magnitude higher than in comparable tg mouse or rabbit models [2, 5, 14] and allowed a preclinical proof-of-principle efficacy study for a peptidic HIV entry inhibitor and a reverse transcriptase inhibitor .
Despite this advancement, significant limitations exist in the current model: levels of plasma viremia are low and only transient . To a large extent, these limitations may be due to a cell type-specific block to productive HIV-1 infection in hCD4/hCCR5-tg rats. Primary T-cells, in contrast to macrophages from these animals, did not support a productive R5 HIV-1 infection [7, 12]. Following up on this observation, we recently compared the efficiency of early steps of the HIV replication cycle in infected primary T-cells from hCD4/hCCR5-tg rats and human donors. Remarkably, levels of viral entry, HIV-1 cDNA production, nuclear import of the preintegration complex, as well as the frequency of integration into the host genome, were similar in both species . In contrast, a profound post-entry impairment was evident for early HIV gene expression in primary rat T-cells . We reasoned that a transcriptional deficit due to an inefficient Tat-dependent HIV-1 LTR transactivation may underlie this inefficient viral gene expression in rats as it does in mice [15, 16]. Cyclin T1 (CycT1) is a key component of the positive transcription elongation factor b (P-TEFb) , which is critical for efficient elongation of many cellular as well as HIV transcripts (for review ). In mice, the inability of CycT1 to support the interaction with the transactivation response (TAR) element when bound to Tat has been mapped to one critical amino acid (tyrosine-261; cytosine-261 in hCycT1) [18–21]. Intriguingly, rat and mouse CycT1 have a 96% sequence homology and both contain tyrosine-261 . While ectopic expression of hCycT1 in NIH3T3 cells resulted in a marked, ~10- to 100-fold enhancement of LTR-driven gene expression, this effect was quite moderate, only ~3-fold in Rat2 cells [1, 4, 6, 9], challenging the potential benefit of ectopic expression of hCycT1 in the rat species. However, evidence in support of such an approach was provided by an experiment, in which transient coexpression of hCycT1 and proviral HIV reporter DNA in nucleofected primary rat T-cells resulted in a marked enhancement of early viral gene expression . This suggested that an underlying transcriptional defect linked to the non-functional rat orthologue was, at least in part, responsible for the gene expression phenotype in native rat T-cells.
In NIH3T3 or Rat2 cells, additional less-defined blocks in the late phase of the HIV-1 replication cycle add up to a profound drop in the yield of viral progeny, up to 104-fold or 102-fold, respectively, from a single round of replication [1, 4, 9, 12, 22, 23]. In both the mouse and rat fibroblast cell line, these late-stage barriers display a recessive phenotype and likely result from non-functional rodent cofactors since they can be surmounted in rodent-human heterokaryons. In striking contrast to all mouse cell line studies, mice that carry a full-length HIV-1 provirus have been reported to secrete high levels of infectious HIV-1 with viremia levels of >60,000 HIV RNA copies per ml . Moreover, in T-cells and macrophages from these provirus-carrying mice, tg co-expression of hCycT1 markedly boosted HIV-1 transcription and virus production [25, 26].
On a more general level, the transcriptional phenotype as well as the severe late-phase limitations described in rodent cell lines may thus not necessarily be predictive for the ability of primary cells to support these steps of the HIV-1 replication cycle. In the current study, we generated rats that transgenically express hCycT1 in a cell type-specific manner to explore their suitability for enhancing HIV-1 transcription and gene expression in primary T-cells and macrophages. Moreover, we wanted to probe whether ameliorating the transcriptional deficit by hCycT1 transgenesis may render primary T-cells from rats that transgenically co-express the HIV receptor complex susceptible for a productive and spreading R5 HIV-1 infection.
Construction of tg rats that selectively express hCycT1 in HIV target cells
All four tg rat lines expressed significant levels of hCycT1 in thymocyte extracts as assessed by a species-specific western blot, and founder line 44, displaying the highest hCycT1 level, was selected for further studies (data not shown). F2 progeny did not reveal any gross histopathology (data not shown), and offspring from this hCycT1-tg line have generally been healthy. The expression pattern of hCycT1 was examined in select tissues and purified cell populations from hCycT1-tg rats (Fig. 1C–E). First, hCycT1 expression was readily detectable in rCD4 T-cell-rich thymocyte extracts from hCycT1-tg rats, but not from a non-tg (n-tg) littermate (Fig. 1C). Second, the T-cell subset-specific expression of hCycT1 was analyzed in rCD4- and rCD8-positive splenocytes separated by antibody-coupled magnetic beads (purities of 94% and 93%, respectively; data not shown). A low, but significant hCycT1 expression was detectable only in the rCD4-positive, but not in the rCD8-positive, purified splenocyte fractions of both hCycT1-tg animals (Fig. 1D, * hCycT1). Third, hCycT1 expression was found in spleen-derived macrophages from the two hCycT1-tg rats tested as well as monocyte-derived macrophages (MDM) from a human donor, but not in macrophages from a n-tg control rat (Fig. 1E). Thus, expression of hCycT1 has been targeted to the desired, biologically relevant cell types in tg rats. This finding is consistent with the exclusive expression of hCCR5 or hCD4 on these rat cells, employing the identical or a closely related transgene vector backbone, respectively , and with the targeted expression of hCycT1 in tg mice [10, 25, 26]. Furthermore, it provides the conceptual basis to generate potentially more susceptible rats through interbreeding of these different tg rat lines to achieve expression of all of these human transgenes in the same HIV target cells.
Primary T-cells from hCycT1-tg rats support markedly elevated levels of early HIV gene expression
We expanded our HIV gene expression analysis to rat macrophages, the second major HIV target population. As reported, early HIV-1NL4-3 gene expression was comparable and statistically indistinguishable for infected macrophages derived from n-tg rats and MDM from human donors . Here, hCycT1 transgenesis did not have an enhancing effect (Fig. 5C, left panel). For HIV-2ROD-A, a trend towards higher viral gene expression was observed for macrophages from hCycT1-tg rats compared to n-tg rats, but this difference did not reach statistical significance (Fig. 5C, right panel). Thus, infected primary macrophages from rats display levels of early HIV gene expression similar to those in human MDM, indicating that hCycT1 transgenesis is not a requirement for robust HIV gene expression in the monocyte/macrophage lineage in rats. Collectively, these results show a cell type-specific ability of primary rat cells to support HIV LTR-driven early gene expression and to allow an elevation of early HIV gene expression upon tg expression of hCycT1. The elevated levels of gene expression from the HIV nef locus reach human levels in infected T-cells from some hCycT1-tg rats.
HIV gene expression in transgenic rat T-cells
This transcriptional phenotype was found to be a stable characteristic of individual rats: comparable results were obtained for several independently established T-cell cultures from blood draws of the same tg animals on different days (data not shown). These results indicate that tg expression of hCycT1 is necessary for enhancing early HIV gene expression in infected primary rat T-cells, but currently unknown endogenous factors appear to play an additional critical regulatory role for HIV gene expression.
T-cells from triple-tg rats do not support a productive HIV-1 infection, despite enhanced early gene expression
Previously, we found that T-cells from hCD4/hCCR5-tg rats do not support a spreading HIV-1 infection, despite efficient virion entry [3, 7, 12]. Here, we determined if the enhancement in viral gene expression mediated by hCycT1 transgenesis could translate into a beneficial effect in the context of an infection with replication-competent R5 HIV-1 viruses. Triple-tg rats, heterozygous for hCD4, hCCR5 and hCycT1, were obtained through interbreeding, and their transgene status was determined by flow cytometry (hCD4/hCCR5) and PCR (hCycT1).
Identification of an HIV-1 GFP reporter virus that displays characteristics of a spreading infection in primary T-cells from hCD4/hCCR5-tg rats
We also explored whether HIV-1R7/3 YU-2 Env GFP differs in its transcriptional phenotype in the rat-human species comparison from HIV-1NL4-3 GFP, the latter being the HIV-1 strain used in the experiments described above (Figs. 2, 3, 4, 5, 6, 7). Interestingly, analysis of the MFI of GFP of the infected T-cells as a surrogate for levels of early HIV-1 gene expression revealed that HIV-1R7/3YU-2 Env GFP did not display a significant difference between the two species (Fig. 8C, right panel). In contrast, HIV-1NL4-3 GFP showed a marked, on average 5.4-fold reduction (p = 0.007) in T-cells from these n-tg rat donors compared to the human reference controls (Fig. 8C, left panel), confirming the above described transcriptional phenotype for this viral strain (Figs. 2, 3, 4, 5, 6, 7). Thus, the HIV transcriptional phenotype in rat cells markedly depends on the employed HIV-1 strain and HIV-1R7/3 YU-2 Env GFP is superior to the HIV-1NL4-3-based virus.
Parallel infection with a second replication-competent R5 HIV-1 GFP reporter virus, HIV-1NL4-3 92TH014-2 Env GFP, resulted in a productive infection of human T-cells as seen both by an increase in the percentage of GFP-positive cells and p24 antigen in supernatants (Fig. 9A, 9B, right panels). In contrast, neither virological readout provided evidence for a spreading infection in hCD4/hCCR5-tg rat T-cells (Fig. 9A, B, left panels; and data not shown) indicating that the infection phenotype observed for HIV-1R7/3 YU-2 Env GFP is not a universal property of replication-competent HIV-1 GFP reporter viruses. Collectively, our results provide evidence that primary rodent T-cells expressing a functional HIV receptor complex have the capacity to support a spreading, most likely cell-to-cell-mediated infection of at least one HIV-1 strain, despite an absence of detectable capsid antigen in culture supernatants.
Transgenic expression of hCycT1 significantly enhances replication of HIV-1R7/3YU-2 Env GFP
All rat T-cell cultures supported an efavirenz-sensitive, spreading infection reflected by an increase of the percentage of GFP-expressing cells over the course of 15 days (Fig. 10B). Of note, individual wells of T-cells from triple-tg rat 463 reached remarkably high percentages of GFP-positive cells (up to 12%) at day 10 and/or 15 p.i. Importantly, cultures from the group of hCD4/hCCR5/hCycT1-tg rats (Fig. 10B, lower panels) displayed a moderate, but significant enhancement of infection compared to the group of hCD4/hCCR5-tg animals (Fig. 10B, upper panels) (p = 0.02; linear model variance analysis). Finally, we assessed whether the infection of HIV-1R7/3 YU-2 Env GFP or of prototypic R5 HIV-1 wildtype viruses in triple-tg rat T-cell cultures can be detected by quantification of cell-associated levels of p24 antigen over time. While this was possible for infected human T-cell cultures with levels ranging from 1-11 ng/ml, no p24 levels above background were found in rat T-cells (data not shown). Collectively, based on the kinetics and characteristics of cell-associated early gene expression, hCycT1 transgenesis can facilitate replication of an HIV-1 GFP reporter virus in primary rat T-cells.
To further develop a small animal model that is highly permissive for de novo infection by HIV-1, we sought to expand on our earlier results in hCD4/hCCR5-tg rats [3, 7, 12, 13]. Here, we generated rats that transgenically express hCycT1 in a cell type-specific manner to explore their suitability for enhancing the susceptibility of this important cell type in the multi-tg rat model.
In infected rat T-cells, hCycT1 transgene expression boosted early HIV gene expression ~3- to 7-fold compared to n-tg littermates. Importantly, cultures from ~1/4 of hCycT1-tg rats reached levels of HIV gene expression within the average range of infected human T-cells. However, while hCycT1 expression was clearly required, no correlation could be established between steady-state expression levels of hCycT1 and the ability of infected cultures to support early HIV gene expression. This finding is consistent with a scenario in which endogenous factors in concert with hCycT1 play a decisive role in regulating HIV LTR-driven gene expression in rat T-cells. Alternatively, only a subset of CD4 T-cells may be capable of translating hCycT1 expression into an enhanced gene expression and in these cells transgene expression levels may still correlate with the functional impact.
In principle, this could involve the recruitment of transcription factors (e.g., NF-κB, SP1, NFAT) to the 5'-LTR as well as factors regulating the activity of P-TEFb. Interestingly, no cellular gene is as sensitive to the availability of P-TEFb as the genes of HIV-1 (for review ). So far, several positive regulators of P-TEFb and HIV-1 LTR transactivation have been reported, including bromodomain protein Brd4 [29, 30], NF-κB , and the DNA-dependent ATPase subunit Brm of the SWI/SNF chromatin-remodeling complex . Negative regulators have also been found, including the noncoding 7SK small nuclear RNA [33, 34], HEXIM1 , the DRB sensitivity-inducing factor (DSIF) , and negative elongation factor (NELF) . Furthermore, transcription factor recruitment at contiguous LTR regions is partly dependent on histone acetylation as well as the viral Tat protein . Conceivably, the interaction of such endogenous factors with the Tat/hCycT1-containing P-TEFb complex may be different in rats than in humans. Similarly, dominant-negative activities of CycT1 or CycT2 of rat origin have to be considered in a hCycT1-tg context.
Recently, Sun et al. reported that hCycT1 transgenesis in mice, employing the identical transgene vector, also resulted in a cell type-specific expression in CD4 T-cells, macrophages as well as microglia [25, 26]. Importantly, crossing HIV-1JR-CSF-tg mice, which carry two to four proviruses, with these hCycT1-tg mice revealed a marked increase in the production of infectious HIV-1 in both T-cells and macrophages . HIV-1 p24 concentrations in supernatants were still lower than the levels typically reached in dynamically infected human cultures. In a more refined characterization of T-cells from these hCycT1-tg mice, Zhang et al. demonstrated HIV-1 RNA expression per infected T-cell was only 10% of that of human references , indicating that the transcriptional deficit also in this rodent had only partially been overcome by hCycT1 transgenesis. Of note, this analysis required a secondary T-cell receptor stimulation to circumvent a peri-integrational block in primary mouse T-cells, which is absent in the rat species . Interestingly, infected rat macrophages pose an exception to the otherwise species-specific impairment at the level of early HIV-1 gene expression . As shown herein, tg expression of hCycT1 does not translate into an enhanced viral gene expression in this primary cell type, and already macrophages from n-tg rats are at a level comparable to human MDM. This may, in part, relate to the ability of HIV-1 to exploit a distinct set of nuclear transcription factors and alternative mechanisms of transcriptional regulation in macrophages compared to other cell types, including T-cells (for review [39–41]). In addition, hCycT1-dependence and species-specific differences of HIV LTR driven gene expression appear to be less pronounced or even absent when levels of gene expression per cell are low. This was observed both for macrophages (Fig. 5C) and T-cells infected with the HIV-1 strain R7/3 with apparently lower intrinsic LTR activity (Fig. 8C, compare left and right panel). Notably, macrophages from hCD4/hCCR5-tg rats are the only primary non-human cells reported to allow a productive HIV-1 infection, albeit at lower levels than in human MDM [4, 12, 42]. The general ability of macrophages to support HIV LTR-driven transcription and, related to that, their responsiveness to transgenic hCycT1 expression, appears to be remarkably different in rats and mice .
Zhang et al. also characterized the late phase in primary T-cells from hCycT1-tg mice ex vivo and report post-transcriptional defects at the levels of Gag expression, Gag processing, Gag release and virus infectivity . They estimated that the post-integration defects alone add up to a 300- to 500-fold reduction in the yield of infectious virus after a single cycle of HIV-1 replication. It is currently unclear why T-cells from provirus-tg mice appear to be much less restricted in supporting these steps of the HIV-1 replication cycle [24–26]. Limitations for several distinct late-phase steps in rodent cells have been proposed, including the Rev-dependent export of HIV-1 RNA [1, 9, 43–45] Gag trafficking and virion assembly [1, 9, 10, 45], both inhibitory and supportive functions of TRIM family members , as well as the Vif-resistance of mouse APOBEC3G . These findings are of high relevance for future analyses of the late-phase defect in T-cells from rats and possible additional genetic modifications of the host.
We identify HIV-1R7/3 YU-2 Env GFP as a virus, the behavior of which in tg rat T-cells ex vivo displays key characteristics of a spreading, primarily cell-to-cell-mediated infection: first, GFP expression from the nef locus, a surrogate for early viral gene expression in infected cells, increased continuously over periods of 2 weeks with peak levels comparable to human reference cultures. This was not a general property of replication-competent HIV-1 GFP reporter viruses since another R5 strain failed to recapitulate this phenotype. Second, this increase was sensitive to efavirenz addition 18 h p.i. and also not seen for an env-deficient single-round virus. This demonstrates the requirement for multiple rounds of replication involving reverse transcription. Third, the lack of significant p24 levels in supernatants from infected rat T-cell cultures and the successful transfer of infection to naïve cultures only through cells, but not supernatant from infected cultures, indicates a primarily cell-to-cell-mediated spread. Levels of p24 antigen per infected rat T-cell as well as the overall percentage of infected T-cells in culture may have been too low to detect a spread by quantification of cell-associated p24 levels. This challenging observation warrants further investigations. It will be interesting to investigate the genetic determinants in HIV-1R7/3 YU-2 Env GFP that underlie its ability to propagate in tg rat T-cells. Through such a genetic approach and forced adaptation of this or other HIV-1 strains for replication in the improved transcriptional context of triple-tg rat T-cells, the evolution of a highly rat-adapted HIV-1 strain may be feasible. Moreover, the molecular characterization of such an adapted strain could greatly facilitate the identification of host determinants that are critical regulators of late phase-steps of HIV replication.
The hCD4/hCCR5-tg rats have been reported . The tg vector pMΦE4A.CyclinT1 (Fig. 1A), which encodes a 1.15-kb cDNA fragment of hCycT1 and carries a cassette containing the murine CD4 enhancer/promoter and the human CD4 intronic sequence, which encompasses the macrophage enhancer and the CD4 silencer elements was recently described . For generation of hCycT1-tg rats, the transgene vector was linearized using the flanking NotI sites and microinjected into male pronuclei of fertilized oocytes from outbred Sprague-Dawley rats. Founders for hCycT1-tg rats were identified by PCR amplification of a hCycT1-specific sequence in tail biopsy DNA samples (5'-primer: GAT ACT AGA AGT GAG GCT TAT TTG, 3'-primer: CAG ATA GTC ACT ATA AGG ACG AAC) and selected for further matings with n-tg Sprague-Dawley rats. Transgene expression in progeny was demonstrated by western blot detection of hCycT1 in thymocyte extracts. Heterozygous hCD4/hCCR5/hCycT1-tg animals were generated by interbreeding of homozygous hCD4/hCCR5-tg rats with hCycT1-tg rats. Animals were kept in the IBF animal facility of Heidelberg University.
The set-up and cultivation of primary cultures for T-cells and macrophages isolated from buffy coats of human donors or rat spleen have been described [4, 12]. PBMC from rat blood were purified and cultured by drawing 1.5 ml of peripheral blood from the Vena jugularis of anaesthetized rats and isolating the mononuclear cells on Ficoll-hypaque gradients. PBMC were activated using recombinant human interleukin-2 (IL-2) (20 nM; Biomol) in combination with phytohemagglutinin-P (human) or concanavalin A (Con A) (rat) (each at 1 μg/ml, Sigma). At the time of HIV-1 infection cultures typically contained ~90–95% CD3-positive T-cells, with NK cells constituting the majority of non-T-cells [27, 42]. The original sources and cultivation of TZM-bl and 293 T cells has been reported .
The molecular clone pNL4-3 E--EGFP, encoding an env-defective replication-deficient HIV-1NL4-3 carrying an egfp gene within the nef locus (HIV-1NL4-3 GFP) , was a gift of Nathaniel Landau via the NIH AIDS Research and Reference Program. The HIV-2 molecular clone pROD-A, encoding an env-defective replication-deficient HIV-2-based virus carrying an egfp gene within the nef locus (HIV-2ROD-A GFP) was provided by Matthias Dittmar . The production of VSV-G pseudotyped HIV stocks has been described . The replication-competent R5 strains HIV-1R7/3 YU-2 Env GFP  and HIV-1NL4-3 92TH014-2 Env GFP  were gifts from Mark Muesing and Jan Münch, respectively. The first strain has a truncated vpr gene and is devoid of a functional vpu gene . The original sources of HIV-1YU-2, HIV-1Ba-L, and HIV-1JR-FL have been reported . Virus-containing supernatants were concentrated using Centricon Plus-70 spin columns (Millipore) and then purified through a 20% sucrose cushion (27,000 g, 4°C, 60 min). The virion-enriched pellet was resuspended in culture medium, frozen in liquid nitrogen and stored at -80°C. All HIV stocks were characterized for infectious titer on TZM-bl cells and HIV-1 stocks for p24 concentration by ELISA . For analysis of cell-associated p24 levels, cells were lysed in 1% Triton X-100 in PBS-Tween and quantified by ELISA.
HIV Tat and LTR reporter constructs
pBC12/CMV HIV-2 Tat  (pHIV-2 Tat) was a gift from Brian Cullen. pCMV4-Tat2ex carries the second exon of the tat gene from HIV-1NL4-3 (pHIV-1 Tat). To generate minimal HIV LTR reporter plasmids, HIV LTR and gag-leader sequences were amplified from pNL4-3 and pROD10, respectively, and subcloned via introduced AseI and NheI sites in pEGFP-N1 vector (Invitrogen) replacing the CMV-IE promoter.
Western blot analysis
Cells were lysed in buffer A (50 mM HEPES, 135 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA), and 1 × protease inhibitor cocktail (Sigma), pH 7.2, for 1 h at 4°C. Lysates were collected after centrifugation at 13,200 × g for 20 min at 4°C and analyzed for protein concentration using the BCA protein assay (Pierce). Proteins were run on a 12% SDS-PAGE and transferred onto nitrocellulose. Blots were sequentially probed with mouse anti-hCycT1 monoclonal antibody sc-8127 and rabbit antiserum sc-153 against ERK2 (both from Santa Cruz). After secondary antibody treatment, the blots were exposed to autoradiographic films using the ECL system.
Antibody-coupled bead selection of rat splenocytes
rCD4- and rCD8-positive primary cells were purified from freshly isolated rat splenocytes by positive selection with the MACS bead technology (Miltenyi Biotec). As primary reagent, phycoerythrin (PE)-conjugated monoclonal antibodies against rCD4 (clone OX-8) or rCD8 (clone OX-35; both from BD Pharmingen) were used followed by anti-PE magnetic beads. The column purification of labeled cells was carried out according to the manufacturer's instructions, and the purity of selected cell populations was analyzed by flow cytometry.
Activated primary rat T-cells were transfected with proviral reporter plasmids, or with LTR and Tat plasmids, by nucleofection and analyzed by flow cytometry one day later, in principle as reported .
Cells were either nucleofected with pHIV-1NL4-3 GFP, pHIV-2ROD-A GFP, or pHIV-1NL4-3 LTR GFP, pHIV-2ROD-A LTR GFP in the absence or presence of Tat expression plasmids, or infected with the corresponding VSV-G pseudotypes, or HIV-1R7/3 YU-2 Env GFP, or HIV-1NL4-3 92TH014-2 Env GFP. At the indicated time points viable cells were analyzed for the MFI of GFP in and/or the percentage of GFP-positive cells on a FACSCalibur using BD CellQuest Pro 4.0.2 Software (BD Pharmingen).
Unpaired Student's t-test analysis was calculated with the software MS Excel 2003. For the data presented in Fig. 10B a linear model variance analysis (repeated measurement design) was performed. A result was considered significant when p < 0.05.
We thank Dr. Hans-Georg Kräusslich for continuous support. We are grateful to Drs. Brian Cullen, Matthias Dittmar, Beatrice Hahn, Nathaniel Landau, Jan Münch, and Mark Muesing for the gift of reagents, to Dr. Oliver Fackler for comments on the manuscript, and to Gary Howard for editorial assistance. We thank Dr. Heiko Becher for statistical support and Reinhold Schmitt and Silvio Krasemann for animal handling. This work was supported by the Deutsche Forschungsgemeinschaft (grant Ke 742/2; project B17 of SFB544), subcontract R0051-B from the J. David Gladstone Institutes to O.T.K., by the ExCellENT-HIT consortium (LSH-CT-2006-037257) of the European Union to O.T.K., by NIH grant R21-AI46258 to M.A.G., and by NIH grant R01-MH64396 to M.A.G. and W.C.G. This work was supported in part by a grant from a subproject (MSA-06-441) provided by CONRAD, Eastern Virginia Medical School under a Cooperative Agreement (HRN-A-00-98-00020-00) with the United States Agency for International Development (USAID) and the Bill & Melinda Gates Foundation. During part of this study, O.T.K. was supported by a Howard Hughes Medical Institute Physician Postdoctoral Fellowship. C.G. is recipient of a fellowship from the Peter and Traudl Engelhorn-Stiftung. N.M. is indebted to the Landesstiftung Baden-Württemberg for financial support.
- Bieniasz PD, Cullen BR: Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol. 2000, 74 (21): 9868-9877. 10.1128/JVI.74.21.9868-9877.2000.PubMed CentralView ArticlePubMed
- Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, DePinho RA, Goldstein H: Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA. 1997, 94 (26): 14637-14641. 10.1073/pnas.94.26.14637.PubMed CentralView ArticlePubMed
- Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Krausslich HG, Greene WC, Keppler OT: Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology. 2007, 4: 53-10.1186/1742-4690-4-53.PubMed CentralView ArticlePubMed
- Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA: Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol. 2001, 75 (17): 8063-8073. 10.1128/JVI.75.17.8063-8073.2001.PubMed CentralView ArticlePubMed
- Sawada S, Gowrishankar K, Kitamura R, Suzuki M, Suzuki G, Tahara S, Koito A: Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med. 1998, 187 (9): 1439-1449. 10.1084/jem.187.9.1439.PubMed CentralView ArticlePubMed
- Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 1998, 92 (4): 451-462. 10.1016/S0092-8674(00)80939-3.View ArticlePubMed
- Goffinet C, Allespach I, Keppler OT: HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci USA. 2007
- Landau NR, Warton M, Littman DR: The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature. 1988, 334 (6178): 159-162. 10.1038/334159a0.View ArticlePubMed
- Mariani R, Rutter G, Harris ME, Hope TJ, Krausslich HG, Landau NR: A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol. 2000, 74 (8): 3859-3870. 10.1128/JVI.74.8.3859-3870.2000.PubMed CentralView ArticlePubMed
- Zhang JX, Diehl GE, Littman DR: Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS ONE. 2008, 3 (4): e2035-10.1371/journal.pone.0002035.PubMed CentralView ArticlePubMed
- Cohen J: Building a small-animal model for AIDS, block by block. Science. 2001, 293 (5532): 1034-1036. 10.1126/science.293.5532.1034.View ArticlePubMed
- Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA: Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med. 2002, 195: 719-736. 10.1084/jem.20011549.PubMed CentralView ArticlePubMed
- Münch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Giménez-Gallego G, Sánchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007, 131 (6): 1059-1071. 10.1016/j.cell.2007.10.014.View ArticlePubMed
- Snyder BW, Vitale J, Milos P, Gosselin J, Gillespie F, Ebert K, Hague BF, Kindt TJ, Wadsworth S, Leibowitz P: Developmental and tissue-specific expression of human CD4 in transgenic rabbits. Mol Reprod Dev. 1995, 40 (4): 419-428. 10.1002/mrd.1080400405.View ArticlePubMed
- Alonso A, Cujec TP, Peterlin BM: Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. J Virol. 1994, 68 (10): 6505-6513.PubMed CentralPubMed
- Hart CE, Galphin JC, Westhafer MA, Schochetman G: TAR loop-dependent human immunodeficiency virus trans activation requires factors encoded on human chromosome 12. J Virol. 1993, 67 (8): 5020-5024.PubMed CentralPubMed
- Zhou Q, Yik JH: The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev. 2006, 70 (3): 646-659. 10.1128/MMBR.00011-06.PubMed CentralView ArticlePubMed
- Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR: Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. Embo J. 1998, 17 (23): 7056-7065. 10.1093/emboj/17.23.7056.PubMed CentralView ArticlePubMed
- Fujinaga K, Cujec TP, Peng J, Garriga J, Price DH, Grana X, Peterlin BM: The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol. 1998, 72 (9): 7154-7159.PubMed CentralPubMed
- Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA: The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 1998, 12 (22): 3512-3527. 10.1101/gad.12.22.3512.PubMed CentralView ArticlePubMed
- Kwak YT, Ivanov D, Guo J, Nee E, Gaynor RB: Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. J Mol Biol. 1999, 288 (1): 57-69. 10.1006/jmbi.1999.2664.View ArticlePubMed
- Coskun AK, van Maanen M, Nguyen V, Sutton RE: Human chromosome 2 carries a gene required for production of infectious human immunodeficiency virus type 1. J Virol. 2006, 80 (7): 3406-3415. 10.1128/JVI.80.7.3406-3415.2006.PubMed CentralView ArticlePubMed
- Mariani R, Rasala BA, Rutter G, Wiegers K, Brandt SM, Krausslich HG, Landau NR: Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol. 2001, 75 (7): 3141-3151. 10.1128/JVI.75.7.3141-3151.2001.PubMed CentralView ArticlePubMed
- Browning Paul J, Wang EJ, Pettoello-Mantovani M, Raker C, Yurasov S, Goldstein MM, Horner JW, Chan J, Goldstein H: Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retroviruses. 2000, 16 (5): 481-492. 10.1089/088922200309142.View ArticlePubMed
- Sun J, Soos T, Kewalramani VN, Osiecki K, Zheng JH, Falkin L, Santambrogio L, Littman DR, Goldstein H: CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate. J Virol. 2006, 80 (4): 1850-1862. 10.1128/JVI.80.4.1850-1862.2006.PubMed CentralView ArticlePubMed
- Sun J, Zheng JH, Zhao M, Lee S, Goldstein H: Increased In vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides. J Virol. 2008, 82 (11): 5562-5572. 10.1128/JVI.02618-07.PubMed CentralView ArticlePubMed
- Goffinet C, Keppler OT: Efficient nonviral gene delivery into primary lymphocytes from rats and mice. Faseb J. 2006, 20 (3): 500-502.PubMed
- Wiskerchen M, Muesing MA: Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995, 69 (1): 376-386.PubMed CentralPubMed
- Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K: The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005, 19 (4): 523-534. 10.1016/j.molcel.2005.06.027.View ArticlePubMed
- Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q: Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005, 19 (4): 535-545. 10.1016/j.molcel.2005.06.029.View ArticlePubMed
- Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM: NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell. 2001, 8 (2): 327-337. 10.1016/S1097-2765(01)00314-8.View ArticlePubMed
- Treand C, du Chene I, Bres V, Kiernan R, Benarous R, Benkirane M, Emiliani S: Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. Embo J. 2006, 25 (8): 1690-1699. 10.1038/sj.emboj.7601074.PubMed CentralView ArticlePubMed
- Yang Z, Zhu Q, Luo K, Zhou Q: The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature. 2001, 414 (6861): 317-322. 10.1038/35104575.View ArticlePubMed
- Nguyen VT, Kiss T, Michels AA, Bensaude O: 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature. 2001, 414 (6861): 322-325. 10.1038/35104581.View ArticlePubMed
- Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q: Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell. 2003, 12 (4): 971-982. 10.1016/S1097-2765(03)00388-5.View ArticlePubMed
- Wada T, Takagi T, Yamaguchi Y, Ferdous A, Imai T, Hirose S, Sugimoto S, Yano K, Hartzog GA, Winston F, Wada T, Takagi : DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev. 1998, 12 (3): 343-356. 10.1101/gad.12.3.343.PubMed CentralView ArticlePubMed
- Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H: NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 1999, 97 (1): 41-51. 10.1016/S0092-8674(00)80713-8.View ArticlePubMed
- Lusic M, Marcello A, Cereseto A, Giacca M: Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. Embo J. 2003, 22 (24): 6550-6561. 10.1093/emboj/cdg631.PubMed CentralView ArticlePubMed
- Liou LY, Herrmann CH, Rice AP: HIV-1 infection and regulation of Tat function in macrophages. Int J Biochem Cell Biol. 2004, 36 (9): 1767-1775. 10.1016/j.biocel.2004.02.018.View ArticlePubMed
- Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol. 2003, 74 (5): 736-749. 10.1189/jlb.0403180.View ArticlePubMed
- Venzke S, Keppler OT: The role of macrophages in HIV infection and persistence. Expert Rev Clin Immunol. 2006, 2 (4): 613-626. 10.1586/1744666X.2.4.613.View ArticlePubMed
- Keppler OT, Allespach I, Schuller L, Fenard D, Greene WC, Fackler OT: Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol. 2005, 79 (3): 1655-1665. 10.1128/JVI.79.3.1655-1665.2005.PubMed CentralView ArticlePubMed
- Trono D, Baltimore D: A human cell factor is essential for HIV-1 Rev action. Embo J. 1990, 9 (12): 4155-4160.PubMed CentralPubMed
- Zheng YH, Yu HF, Peterlin BM: Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat Cell Biol. 2003, 5 (7): 611-618. 10.1038/ncb1000.View ArticlePubMed
- Swanson CM, Puffer BA, Ahmad KM, Doms RW, Malim MH: Retroviral mRNA nuclear export elements regulate protein function and virion assembly. Embo J. 2004, 23 (13): 2632-2640. 10.1038/sj.emboj.7600270.PubMed CentralView ArticlePubMed
- Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W: TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 2008, 4 (2): e16-10.1371/journal.ppat.0040016.PubMed CentralView ArticlePubMed
- Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003, 114 (1): 21-31. 10.1016/S0092-8674(03)00515-4.View ArticlePubMed
- Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995, 206 (2): 935-944. 10.1006/viro.1995.1016.View ArticlePubMed
- Reuter S, Kaumanns P, Buschhorn SB, Dittmar MT: Role of HIV-2 envelope in Lv2-mediated restriction. Virology. 2005, 332 (1): 347-358. 10.1016/j.virol.2004.11.025.View ArticlePubMed
- Münch J, Rajan D, Schindler M, Specht A, Rucker E, Novembre FJ, Nerrienet E, Muller-Trutwin MC, Peeters M, Hahn BH, Kirchhoff F: Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol. 2007, 81 (24): 13852-13864. 10.1128/JVI.00904-07.PubMed CentralView ArticlePubMed
- Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR: Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. J Virol. 1999, 73 (7): 5777-5786.PubMed CentralPubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.